Clinical Trials Browser

Phase 2 × Disease × obinutuzumab × Clear all

NCT03755947 2021-02-02

Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

Phase 2 Completed

LymphoidOther hematologic neoplasm

Disease, Leukemia, Lymphocytic, Chronic, B-Cell